Clinical Studies in Ki-CONNECT Recruiting

Types of trial Trial name Department
Investigator-initiated trial Phase I Single-Administration Study of TRG035 in Healthy Adults Department of Early Clinical Development
Corporate-sponsored trial Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Department of Breast Surgery
Corporate-sponsored trial [M24-742]First-in-Human Study of ABBV-969 in Metastatic Castration-Resistant Prostate Cancer Department of Early Clinical Development
Corporate-sponsored trial A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (J5A-OX-JZWA) Department of Early Clinical Development
Corporate-sponsored trial Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2) Department of Medical Oncology
Corporate-sponsored trial PSMA-DC: An Open-label study comparing lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617) versus observation in PSMA positive OMPC(CAAA617D12302). Department of Radiation Oncology and Image-Applied Therapy
Corporate-sponsored trial Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1) Department of Hematology
Corporate-sponsored trial Phase I Study of AK1910 in Healthy Japanese Subjects, Healthy Caucasian Subjects, Patients with Systemic Lupus Erythematosus (Single Dose and Multiple Dose Study) Department of Rheumatology and Clinical Immunology
Investigator-initiated trial Investigator-initiated phase 1 trial of antisense oligonucleotide against TUG1 for recurrent glioblastoma (TUG trial) Department of Neurosurgery
Corporate-sponsored trial First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies Department of Hematology
Corporate-sponsored trial [M23-385]A Phase 1 study of ABBV-706 alone or in combination in adult subjects with advanced solid tumors. Department of Early Clinical Development
Corporate-sponsored trial [M24-427]ABBV-400 in Select Advanced Solid Tumor Indications Department of Early Clinical Development
Corporate-sponsored trial [M24-311]Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous(IV)ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab Department of Early Clinical Development
Corporate-sponsored trial A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Department of Respiratory Medicine
Corporate-sponsored trial [M20-638] A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide(R2)Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma(EPCORE FL-1)( [M20-638] EPCORE FL-1) Department of Hematology
Corporate-sponsored trial Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) Department of Breast Surgery
Corporate-sponsored trial AB122 Platform study Department of Medical Oncology
Corporate-sponsored trial A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01) Department of Early Clinical Development
Corporate-sponsored trial A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy(TROPION-Breast03) Department of Breast Surgery
Investigator-initiated trial A Phase 1 Study of Lomustine and PCV in Japanese Patients with Glioma(LOMG) Department of Neurosurgery
Investigator-initiated trial PRIME Study (PRIME Study) Department of Nephrology
Investigator-initiated trial NCCH2101/MK011 trial (Perfume trial) Department of Medical Oncology
Corporate-sponsored trial A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician’s Choice of Endcrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(evERA Breast Cancer) Department of Breast Surgery
Corporate-sponsored trial Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Department of Hematology
Investigator-initiated trial Phase II Trial to Evaluate the Efficacy and Safety of Combination Therapy with Immune Checkpoint Inhibitors and Photodynamic Therapy Department of Medical Oncology
Investigator-initiated trial NCCH2201/MK013 trial (CRYSTAL trial) Department of Hematology
Investigator-initiated trial Phase I/II trial for safety and pharmacokinetics of ENDOPIN in healthy adults and patients with pain Department of Early Clinical Development
Corporate-sponsored trial EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (BB2121-EAP-001) Department of Hematology
Corporate-sponsored trial Study to Assess Adverse Events and Change in Disease Activity in Adult Participants with Advanced Solid Tumors Receiving Intravenous(IV) ABBV-400 Department of Early Clinical Development
Corporate-sponsored trial Lenvatinib + pembrolizumab + chemotherapy compared to pembrolizumab + chemotherapy for the first-line treatment of metastatic esophageal cancer Department of Medical Oncology
Corporate-sponsored trial A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPC (CAAA617A11201) Department of Radiation Oncology and Image-Applied Therapy
Corporate-sponsored trial Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release (JCAR017-EAP-001) Department of Hematology
Investigator-initiated trial PENETRATE Department of Medical Oncology
Investigator-initiated trial Clinical Trial of Alectinib in Patients with ALK positive rare cancer Department of Medical Oncology